MedPage Today July 1, 2024
Natalie Muth, MD, MPH, MBA, RDN

— Prepare patients early for a time when medication is no longer an option

At the November 2022 Obesity Week in San Diego, it was clear something big was happening. A late-breaking session released results of the STEP TEENS phase IIIa trial, showing 16% weight loss in adolescents with obesity treated with once-weekly semaglutide (Wegovy) for 68 weeks. The side effects were manageable and similar to those experienced in adults — nausea, vomiting, constipation.

A month later, semaglutide received FDA approval for weight management in adolescents ages 12 and older. And just a month after that, the American Academy of Pediatrics (AAP) released the first-ever clinical practice guidelines for the treatment of children and adolescents with obesity, including pharmacological options...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Primary care, Provider, Trends
Related Articles:
CDC looks to expand capacity to test for H5N1 bird flu in people
Survey Shows Public Support for Hospital at Home Programs
North Carolina to boost Medicaid pay for hospitals that write off medical debt
Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2024
How RUSH Medical Center Cares for Caregivers

Share This Article